Last reviewed · How we verify
Tislelizumab（neoadjuvant）
Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses.
Tislelizumab is a PD-1 inhibitor that blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, thereby restoring anti-tumor immune responses. Used for Neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC), Neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCC).
At a glance
| Generic name | Tislelizumab（neoadjuvant） |
|---|---|
| Sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Tislelizumab binds to programmed death receptor 1 (PD-1) on T lymphocytes, preventing engagement with its ligands (PD-L1 and PD-L2) expressed on tumor and immune cells. This blockade reverses T cell exhaustion and enhances cytotoxic T cell proliferation and activation against cancer cells. In the neoadjuvant setting, it is administered prior to surgical resection to improve pathological response and potentially enhance long-term outcomes.
Approved indications
- Neoadjuvant treatment for resectable non-small cell lung cancer (NSCLC)
- Neoadjuvant treatment for resectable esophageal squamous cell carcinoma (ESCC)
Common side effects
- Fatigue
- Decreased appetite
- Nausea
- Immune-related adverse events (pneumonitis, hepatitis, colitis)
- Infusion-related reactions
Key clinical trials
- Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) (PHASE3)
- A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of Recurrence (PHASE3)
- Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer (PHASE2)
- Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） (PHASE2)
- Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer (PHASE2)
- Neoadjuvant Therapy With Tislelizumab for dMMR/MSI-H Stage II-III Colorectal Cancer
- Efficacy and Safety of Tislelizumab (BGB-A317) as Neo-Adjuvant Treatment in Participants With Colorectal Cancer (PHASE2)
- Surgery With or Without Neoadjuvant Treatment of SBRT Plus Chemoimmunotherapy in Resectable Locally Advanced Oral and HPV-unrelated Oropharyngeal Squamous Cell Carcinoma (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: